EGFR and non-small cell lung carcinoma: Osimertinib received its first approval from the Food and Drug Administration (FDA) for the treatment of EGFR-T790M-positive NSCLC based on a 6-month improvement in progression-free survival (PFS) compared to PBC in the AURA3 trial and a hazard ratio (HR) for overall survival (OS) of 0.54 after adjustment for the high crossover rate in the study [18,19].